Extending the more generous financial assistance is at the center of a funding fight between Democrats and Republicans on Capitol Hill that shut down the federal government early Wednesday.
ACA premiums could rise 114% if enhanced subsidies lapse: KFF Read More »
The $515 million deal has closed after roughly two years, creating the first hospital system owned by a venture capital company.
General Catalyst’s HATCo finalizes Summa Health acquisition Read More »
Descubre por qué los servidores físicos siguen siendo clave en 2025. Rendimiento, seguridad, cumplimiento normativo e integración con la nube: un pilar esencial para empresas y proyectos científicos. En una era dominada por el cloud computing, la inteligencia art …
El papel de los servidores físicos en la ciencia y la informática moderna Read More »
The agency is looking for ways to detect, assess and mitigate changes to the performance of AI-enabled devices over time.
FDA seeks feedback on monitoring real-world performance of AI devices Read More »
The company hopes to launch its next-generation Watchman system in the second half of 2027 or early 2028.
Boston Scientific unveils plans for new Watchman device Read More »
Despite repeated warnings from telehealth groups, Congress failed to extend the pandemic-era telehealth policies before they lapsed on Oct. 1. Now, providers are scrambling to manage the disruption to virtual care reimbursement and access.
Telehealth flexibilities expire amid government shutdown Read More »
At the heart of the agreement is Pfizer’s $70 billion commitment to U.S.-based manufacturing and an exemption from tariffs for three years. While the reaction was mostly positive from Wall Street, other observers noted that the benefits for patients are unclear at best.
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access Read More »
The medical device industry has a jam-packed year of events for professionals to attend, including the J.P. Morgan Healthcare Conference, DeviceTalks Boston and AdvaMed’s annual medtech meeting.
As with recent rejections for Biogen and Scholar Rock, manufacturing issues stymied a regulatory bid from Fortress Biotech and Sentynl Therapeutics. Fortress said the FDA did not flag problems with the drug’s safety or efficacy.
Fortress, Sentynl Fail To Secure FDA Nod in Rare Pediatric Disease Read More »
Novo Nordisk and Heartseed first partnered in 2021 to develop an investigational cell therapy for heart failure.
Novo Breaks $598M Heartseed Pact Amid ‘Decisive Restructuring’ by New CEO Read More »
